Immunovant, Inc.
IMVT
$15.08
$0.191.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -38.40% | -41.33% | -116.11% | -86.01% | -17.87% |
| Total Depreciation and Amortization | 33.75% | 70.31% | 70.69% | 58.93% | 50.94% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 37.08% | 17.90% | 11.03% | 17.49% | 23.16% |
| Change in Net Operating Assets | -482.60% | -384.55% | 83.32% | 162.46% | -117.06% |
| Cash from Operations | -54.08% | -85.32% | -113.15% | -47.60% | -60.86% |
| Capital Expenditure | -- | -34.00% | -37.40% | -476.47% | -304.44% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -34.00% | -37.40% | -476.47% | -304.44% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 325.36% | 29,086.47% | -99.48% | 393.24% | -22.92% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 325.36% | 29,065.83% | -99.48% | 393.24% | -22.92% |
| Foreign Exchange rate Adjustments | -268.96% | -117.86% | 90.72% | 1,319.77% | 812.77% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -52.68% | 710.53% | -123.34% | -45.03% | -61.81% |